Shared on 13 Nov 25
ELK: Upcoming Medical Material Launch Will Support Increased Market Confidence
Narrative Update on Elkem: Analyst Price Target Revision Analysts have maintained their fair value estimate for Elkem at NOK 29.80. This reflects steady confidence in the company despite minor adjustments to key assumptions such as profit margin and growth projections.
Shared on 29 Oct 25
Fair value Increased 1.64%Analysts have raised their price target for Elkem from NOK 29.32 to NOK 29.80. This change reflects minor adjustments to their expectations for growth, discount rates, and profit margins.
Shared on 15 Oct 25
Fair value Increased 5.01%Elkem's analyst consensus price target has been raised from $27.92 to $29.32, reflecting analysts' expectations of slightly improved revenue growth and a lower discount rate that drives upward fair value adjustments. Valuation Changes The consensus analyst price target has increased from NOK 27.92 to NOK 29.32.
Shared on 25 Sep 25
Fair value Increased 5.76%Elkem's slight improvement in net profit margin has supported an upward revision of the consensus analyst price target from NOK26.40 to NOK27.92. What's in the News Elkem and NTE signed a long-term power purchase agreement for 300 GWh/year renewable power delivery (2028-2037) in Norway’s NO4 area.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 1.92%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.39%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 1.95%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Decreased 0.91%AnalystConsensusTarget has increased revenue growth from 7.1% to 30.2%, decreased profit margin from 9.0% to 6.2% and increased future PE multiple from 5.7x to 8.7x.